Can Dronedarone (Multaq) Be Safely Discontinued in This Patient?
Yes, dronedarone (Multaq) should be discontinued in this patient who has been in stable sinus rhythm for over a year following successful ablation, particularly given his dual-chamber pacemaker and Watchman device.
Rationale for Discontinuation
Primary Indication No Longer Present
The FDA-approved indication for dronedarone is to "reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent AF" 1. Your patient has been AF-free for over a year post-ablation, meaning the primary therapeutic target—preventing AF recurrence and reducing hospitalizations—is no longer relevant.
Guideline Support for Stopping Antiarrhythmics After Successful Ablation
The 2024 ESC guidelines emphasize that antiarrhythmic drug therapy is aimed at symptom reduction, not arrhythmia elimination 2. The 2020 Canadian guidelines explicitly state that "long-term oral antiarrhythmic therapy should not be continued in patients when AF becomes permanent" 3, and by extension, when rhythm control has been definitively achieved through ablation without recurrence, continued AAD therapy lacks justification.
The 2011 Canadian guidelines note that antiarrhythmic drugs should be "reassessed periodically based on both efficacy and side effects" and that "if patients fail to respond to or cannot tolerate a particular drug, an alternative drug may be tried" 4. In your patient's case, the ablation has succeeded where drugs would have been used—making continued dronedarone unnecessary.
Safety Concerns with Continued Dronedarone
Critical contraindications and warnings from the FDA label 1:
- Dronedarone carries a boxed warning for increased mortality in permanent AF and decompensated heart failure
- While your patient doesn't have these specific contraindications, dronedarone has significant adverse effects including hepatotoxicity, pulmonary toxicity, and bradycardia
- The combination of dronedarone with both metoprolol AND diltiazem creates excessive AV nodal blockade risk, particularly in a patient with a pacemaker
The FDA label specifically warns that dronedarone "may provoke excessive bradycardia" when combined with beta-blockers 1, and your patient is on both a beta-blocker (metoprolol 100 mg) and a calcium channel blocker (diltiazem 120 mg)—a triple AV nodal blocking regimen that is potentially hazardous.
Watchman Device Provides Stroke Protection
Your patient has a Watchman left atrial appendage occlusion device, which provides mechanical stroke prevention 5. The 2019 AHA/ACC/HRS guidelines recognize that "percutaneous LAA occlusion may be considered in patients with AF at increased risk of stroke who have contraindications to long-term anticoagulation" 5. While dronedarone has some stroke reduction benefits 3, the Watchman device addresses this concern mechanically.
Specific Concerns About Current Medication Regimen
Excessive Rate Control
Your patient is on three rate-controlling agents simultaneously:
- Metoprolol 100 mg daily (beta-blocker)
- Diltiazem CD 120 mg daily (calcium channel blocker)
- Dronedarone 400 mg twice daily (has rate-controlling properties 4)
The 2011 Canadian guidelines state that dronedarone "may be added for additional rate control in patients with uncontrolled ventricular rates despite therapy with beta-blockers, calcium channel blockers, or digoxin" 4. Your patient is in sinus rhythm with a pacemaker—there is no ventricular rate to control from AF.
Risk of Bradycardia
The combination of metoprolol and diltiazem alone can cause excessive bradycardia 6. Adding dronedarone increases this risk substantially. The FDA label for metoprolol warns about bradycardia, heart block, and cardiac arrest 7, and dronedarone's label notes bradycardia as a common adverse effect (3%) 1.
Clinical Algorithm for Decision-Making
Step 1: Verify rhythm status
- Confirm patient remains in sinus rhythm (ECG, pacemaker interrogation, or ambulatory monitoring)
- Document duration of AF-free interval (>1 year in this case)
Step 2: Assess for recurrence risk factors The 2016 ESC guidelines note that dronedarone "maintains sinus rhythm" but is used when rhythm control is still needed 2. Risk factors for recurrence include:
- Left atrial enlargement >45 mm
- Persistent AF (vs. paroxysmal)
- Heart failure
- Multiple failed ablations
Your patient had successful second ablation with >1 year AF-free—low recurrence risk.
Step 3: Evaluate medication burden
- Count AV nodal blocking agents (this patient has 3)
- Check for drug-drug interactions
- Assess for adverse effects (hepatic, pulmonary, bradycardia)
Step 4: Discontinue dronedarone
- No need for gradual taper (unlike amiodarone, dronedarone has a short half-life of 13-31 hours 8)
- Continue metoprolol and diltiazem for rate control if needed (though even this dual therapy may be excessive in sinus rhythm with a pacemaker)
Post-Discontinuation Monitoring
After stopping dronedarone:
- Monitor rhythm at 1 month, 3 months, then every 6 months (per 2024 ESC guidelines recommending rhythm monitoring "no less often than every 3 months" 9)
- Check liver function tests if baseline abnormalities were present
- Interrogate pacemaker to assess for AF burden
- Consider reducing or discontinuing one of the remaining rate-control agents (metoprolol or diltiazem) if heart rate is excessively slow
Common Pitfalls to Avoid
Don't continue AADs "just in case": The 2016 ESC guidelines emphasize that "clinically successful antiarrhythmic drug therapy may reduce rather than eliminate the recurrence of AF" 2. If there's no AF to reduce, there's no indication.
Don't overlook polypharmacy risks: Three AV nodal blockers in a patient with a pacemaker is excessive and potentially harmful.
Don't confuse post-ablation blanking period with long-term therapy: Some guidelines suggest continuing AADs for 8-12 weeks post-ablation 10, but your patient is >1 year out.
Don't forget the Watchman device provides stroke protection: This addresses one of dronedarone's secondary benefits (stroke reduction 3).